New York's highest court of appeals has held that no-fault insurers cannot deny no-fault benefits where they unilaterally determine that a provider has committed misconduct based upon alleged fraudulent conduct. The Court held that this authority belongs solely to state regulators, specifically New York's Board of Regents, which oversees professional licensing and discipline. This follows a similar recent ruling in Florida reported in this publication.
"No Benefit from Amoxicillan"
A randomized double blind clinical trial of children ages 3-6 recently released from the Agency for Health Care Policy and Research (AHCPR), concluded that "there was no benefit from amoxicillan prophylaxis compared to a placebo control in preventing new AOM (acute otitis media) episodes."
Free of AOM (%)
30-90 Days:
Placebo Group:71% Otitis Free
Daily Amoxicillan Group: 65% Otitis Free
Twice Daily Amoxicillan Group: 62% Otitis Free
3 Months or Longer:
Placebo Group:54% Otitis Free
Daily Amoxicillan Group: 63% Otitis Free
Twice Daily Amoxicillan Group: 60% Otitis Free
SOURCE: Berman S. Continuous twice daily or once daily amoxicillan prophylaxis compared to placebo for children with recurrent otitis media. Agency for Health Care Policy and Research grant no.: RO3 HS07283-02.